Astellas, US Independent Medical Education and Pfizer Global Medical Grants

Call for Independent Medical Education Grant Applications
Oncology – Prostate Cancer

Release Date: October 25th, 2021

I. **Background**

Astellas and Pfizer (collectively, the “Companies”) are committed to supporting high quality, evidence-based independent medical education (“IME”) that seeks to improve the overall safety and quality of patient care and treatment. The intent of this Call for Grant Applications (“CGA”) is to encourage organizations to submit grant applications for independent CME/CE certified education designed to close knowledge gaps identified in the public healthcare landscape, drive measurable improvements in knowledge, competence and performance of healthcare professionals, and advance patient health outcomes. “Independent” means that the projects funded by the companies are the full responsibility of the recipient organization (“Organization”). The Companies have no influence over any aspect of the supported projects and only ask for status updates, interim and final outcomes reports including a description of the impact of the projects.

When responding to this CGA, please adhere to the following principles and established guidelines for Astellas’ IME grant application process. All applications must be submitted online through the Astellas Grant Management System, accessible at [www.astellasgrants.com](http://www.astellasgrants.com).

II. **Eligibility**

<table>
<thead>
<tr>
<th>Geographic Scope:</th>
<th>United States Only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant Eligibility Criteria:</td>
<td>Eligible applicants include hospitals, academic medical centers, medical schools, national-level professional medical associations/societies, medical education companies; and publishers of medical and scientific information.</td>
</tr>
</tbody>
</table>

Collaborations between organizations and within institutions are strongly encouraged. Please note all partners must have a relevant role and the requesting Organization must lead the project.

**For all accredited activities the accrediting organization must be the primary requestor on the grant application.**
III. Requirements

<table>
<thead>
<tr>
<th>Date CGA Issued</th>
<th>October 25, 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Application Deadline</td>
<td>November 30, 2021</td>
</tr>
<tr>
<td>Anticipated Grant Decision Date</td>
<td>December 15, 2021</td>
</tr>
<tr>
<td>Clinical Area-Education</td>
<td>Oncology – Prostate Cancer</td>
</tr>
<tr>
<td>Specific Education Gaps to Be Addressed</td>
<td>The purpose of this CGA is to encourage organizations to submit grant applications for independent CME/CE certified education designed to enhance understanding of the management of hormone sensitive prostate cancer (HSPC), in particular to address gaps related to treatment intensification of mHSPC given numerous randomized trials have demonstrated benefit in this space. Grant proposals should leverage innovative data and content delivery mechanisms including an omnichannel approach. Knowledge gaps in earlier stage prostate cancer which have been identified in the public healthcare landscape include:</td>
</tr>
<tr>
<td></td>
<td>• Knowledge of treatment options in HSPC including treatment intensification and availability of life-prolonging therapies in mHSPC.</td>
</tr>
<tr>
<td></td>
<td>• Barriers to treatment intensification in mHSPC</td>
</tr>
<tr>
<td></td>
<td>• Impact of early treatment on subsequent therapeutic options</td>
</tr>
<tr>
<td></td>
<td>• Integration of NCCN Prostate Cancer Guidelines for mHSPC into clinical practice</td>
</tr>
<tr>
<td></td>
<td>• Novel decision-making tools for healthcare professions to use with patients to support informed patient decision making and drive patient engagement in their care.</td>
</tr>
<tr>
<td></td>
<td>Grant proposals which address multiple gaps from the above list and activities with a national reach and innovative dissemination models will be prioritized.</td>
</tr>
</tbody>
</table>
### How to Submit

Please go to [www.astellasgrants.com](http://www.astellasgrants.com)
LOGIN - Grants for Education and sign in. First-time users will need to “REGISTER NOW”.

Select the following:
Therapeutic Area: Oncology
Disease State: Prostate Cancer

Requirements for submission:
You must include “2020-CGA-03” in the “Activity Title” of your program’s online submission prior to the title.

Complete all required sections of the online application and upload the completed proposal.

| Target Audiences/Formats | Urologists, medical oncologists, radiation oncologists and other HCPs responsible for treatment decisions for patients with prostate cancer. Proposals for independent medical education may include:
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• All activity formats including live or virtual, on-demand (enduring) print materials, utilizing innovative communication channel, apps, social media, digital programs, podcasts and resources or tools for clinical practice. Submissions for future satellite symposia @ ASCO GU22 and ASCO 2022 are encouraged.</td>
</tr>
</tbody>
</table>

### Expected Approximate Monetary Range of Grant Applications

Individual requests up to $225,000 will be considered for funding. Smaller grant budgets are encouraged. Funding of larger amounts will be considered for requests that include multiple activities, such as several live events, enduring activities, and supportive materials and tools. The amount of any grant funded by the Companies for any project may vary from the amount requested. Multi-supported initiatives are preferred.

Collaborations among multiple Organizations are encouraged. Activities with national reach will be prioritized.

### IV. Terms and Conditions

1. This CGA does not commit the Companies or their partners to award a grant or a grant of any particular amount if one is awarded, nor to pay any costs incurred in the preparation of a response to this request.

2. The Companies reserve the right to accept or reject any or all applications received as a result of this request, or to cancel this CGA in part or in its entirety at any time for any reason.
3. All communications about the CGA must be sent to Astellas IME at https://www.astellasgrants.com/. Applicants should not contact other departments within Astellas regarding this CGA. Failure to comply may affect the acceptance of your application.

4. The decision by the Companies to provide a grant will not be determined in a manner that takes into account the volume or value of any business otherwise generated between Astellas or Pfizer and any applicant.

5. Applicant shall have complete control over the content, development and implementation of the education programs and/or materials, including, if applicable, the selection of faculty. Any information provided as part of the program regarding any products, including, without limitation, Astellas and/or Pfizer products, shall be objective and based on scientific methods generally accepted in the medical community.

6. US Transparency Reporting

   A. To enable Astellas to comply with its legal obligations, in the event that any payment or other transfer of value (hereinafter “payment” or “payments”) is provided, either directly or indirectly, to a covered recipient (as defined below) or to another individual or entity at the request or on behalf of a covered recipient, in connection with an approved grant request, Organization shall implement procedures to track the payments and shall report the payments to Astellas upon grant reconciliation and in accordance with any written instructions that Astellas may provide to Organization. Required reporting information includes, but shall not be limited to:

   a. Name and primary business address of covered recipient
   b. For physician covered recipient, NPI, state professional license number and specialty.
   c. Amount of payment
   d. Date of payment
   e. Form of payment
   f. Nature of payment

   B. In addition to these tracking and reporting obligations, Organization shall inform such covered recipient at the time of payment that his/her/its acceptance of such payment may be disclosed in a report filed with government authorities by Astellas as required by law and that government authorities may make the reported information publicly available.

   C. For purposes of this Agreement, the term “covered recipient” has the meaning ascribed to it in 42 C.F.R. § 403.902 and any similar state law which requires tracking and reporting of payments to a government agency for payment transparency purposes.

Frequently Asked Questions related to Astellas’ Sunshine Act Reporting Requirements are available on the website https://www.astellasgrants.com/